Dallas, TX & The Netherlands — October 27, 2025 — Trained Therapeutix, Inc., a biotech company training immunity at its origin with nanomedicines, today announced that it will present a poster titled “RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells” at the Society for Immunotherapy of Cancer (SITC) Annual Meeting taking place November 5 – 9, 2025, in National Harbor, MD.
“At this leading immuno-oncology conference, we are debuting promising data on RIDE-001 — a nanomedicine that trains myeloid progenitor cells to activate anticancer innate immunity — which is built on our platform technology supported by more than two decades of innovative research from our founders,” said Joost Kreijtz, PhD, Chief Executive Officer of Trained Therapeutix (NL), the company’s Dutch subsidiary and operational arm.
Poster Presentation:
| Title: | RIDE-001: A well-tolerated innate immunotherapy to treat cancer by targeting and reprogramming bone marrow progenitor cells |
| Abstract Number: | 1178 |
| Location: | Prince George ABC Exhibit Halls, Gaylord National Resort and Convention Center |
| Date: | Saturday, November 8 |
| Time: | 10:00 a.m. – 6:35 p.m. ET |
About Trained Therapeutix
Trained Therapeutix is a biotechnology company developing a new class of nanomedicines that train immunity at its origin with applications in oncology and immune-mediated diseases. Trained Therapeutix (NL) is the company’s Dutch subsidiary and operational hub for research and development.
